Grant: Doctoral Research Award: Canada Graduate Scholarships
University of Toronto
$105,000.00
Investigating the Underlying Molecular Mechanisms of Brain Arteriovenous Malformations to Identify Novel Therapeutic Targets
EF 2020-21
Résumé
Brain arteriovenous malformation (bAVM) is a vascular disease with the development of abnormal blood vessel connections in the brain. The sites of abnormal connections are constantly under high-pressure blood flow, which makes them prone to rupture and leakage. Patients with bAVM often experience a wide range of neurological symptoms, such as seizure and impaired brain functions. Current treatment for bAVM is limited to surgical procedures, which are highly invasive and carry inherent risks of disabilities or even death. Due to these risks, the surgical procedures are not suitable for a significant portion of the patient population. The lack of a therapeutic drug product for bAVM is largely due to our insufficient understanding about the disease. As such, our group aims to investigate the biology of bAVM development and progression in the search for an effective pharmaceutical treatment option. Previously, our group had identified genetic mutations in the KRAS gene from clinical bAVM samples. These mutations were present specifically in the endothelial cells (ECs), which are cells that line the inner surface of blood vessels. KRAS is a protein that regulates multiple cellular functions, including cell growth, movement and metabolism. Mutations in the KRAS gene alter normal protein activities and disrupt the regulation of important cellular functions. In the present study, we aim to use a human brain EC model to characterize the effects of mutant KRAS on EC growth, movement, metabolism and barrier function. Then, we will use a technique, named phosphoproteomics, to examine changes in the regulation of cellular functions. Separately, we will perform a small molecule screen to search for novel compounds that can rescue the KRAS-induced cellular abnormalities, which will be followed by validations in animal studies. Together, this project contributes to our cumulative understanding of bAVM development and sheds light on novel therapeutic directions for the disease.
Programme
Doctoral Research Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
439334
Name
Wu Ruilin
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Doctoral Research Awards - A
Projecttitle
Investigating the Underlying Molecular Mechanisms of Brain Arteriovenous Malformations to Identify Novel Therapeutic Targets
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$105,000
Cihrequipment2
$0
Programname2
Doctoral Research Award: Canada Graduate Scholarships
Keyworddelim
Brain Arteriovenous Malformations; Cardiovascular Biology; Disease Pathology; Endothelial Biology; High Throughput Screening; Kras Mutations; Molecular Signaling Pathways; Phosphoproteomics; Therapeutic Discovery; Vasculature Development
Abstract
Brain arteriovenous malformation (bAVM) is a vascular disease with the development of abnormal blood vessel connections in the brain. The sites of abnormal connections are constantly under high-pressure blood flow, which makes them prone to rupture and leakage. Patients with bAVM often experience a wide range of neurological symptoms, such as seizure and impaired brain functions. Current treatment for bAVM is limited to surgical procedures, which are highly invasive and carry inherent risks of disabilities or even death. Due to these risks, the surgical procedures are not suitable for a significant portion of the patient population. The lack of a therapeutic drug product for bAVM is largely due to our insufficient understanding about the disease. As such, our group aims to investigate the biology of bAVM development and progression in the search for an effective pharmaceutical treatment option. Previously, our group had identified genetic mutations in the KRAS gene from clinical bAVM samples. These mutations were present specifically in the endothelial cells (ECs), which are cells that line the inner surface of blood vessels. KRAS is a protein that regulates multiple cellular functions, including cell growth, movement and metabolism. Mutations in the KRAS gene alter normal protein activities and disrupt the regulation of important cellular functions. In the present study, we aim to use a human brain EC model to characterize the effects of mutant KRAS on EC growth, movement, metabolism and barrier function. Then, we will use a technique, named phosphoproteomics, to examine changes in the regulation of cellular functions. Separately, we will perform a small molecule screen to search for novel compounds that can rescue the KRAS-induced cellular abnormalities, which will be followed by validations in animal studies. Together, this project contributes to our cumulative understanding of bAVM development and sheds light on novel therapeutic directions for the disease.
Competitiondate
202011
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Wu, Ruilin
Approvedterm
3 ans 0 mois
Cihrcontribution2
~ $105,000~ $0~